Table 4.
Results from clustering of medications data.
| Cluster size | Proportion out of data set | Cluster breakdown | |||||
|---|---|---|---|---|---|---|---|
| Cluster | Number of patients | Proportion out of all patients* | RWD | RCT | RWD | RCT | Most prevalent medication codes** |
| Patients without cluster assignment | 5487 | 19.4% | 17.4% | 27.5% | 71.6% | 28.4% | – |
| 0 | 630 | 2.2% | 0.3% | 9.9% | 11.0% | 89.0% | Ace inhibitors, plain (C09A), Blood glucose lowering drugs, excl. insulins (A10B), Lipid modifying agents, plain (C10A) |
| 1 | 453 | 1.6% | 0.0% | 8.0% | 0.0% | 100.0% | Stomatological preparations (A01A), Topical products for joint and muscular pain (M02A), Antithrombotic agents (B01A), ACE inhibitors, plain (C09A), Other analgesics and antipyretics (N02B), Lipid modifying agents, plain (C10A), Blood glucose lowering drugs, excl. insulins (A10B), Insulins and analogues (A10A), Beta blocking agents (C07A) |
| 2 | 1674 | 5.9% | 7.4% | 0.2% | 99.5% | 0.5% | Other antianemic preparations (B03X), Other analgesics and antipyretics (N02B, Antithrombotic agents (B01A), Opioids (N02A, High-ceiling diuretics (C03C), Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B), Calcium (A12A), Insulins and analogues (A10A), Selective calcium channel blockers with mainly vascular effects (C08C), Beta blocking agents (C07A), Drugs for constipation (A06A), Lipid modifying agents, plain (C10A), Other beta-lactam antibacterials (J01D), Vitamin A and D, incl. combinations of the two (A11C), Antiemetics and antinauseants (A04A), Corticosteroids for systemic use, plain (H02A), Iron preparations (B03A), Hypnotics and sedatives (N05C), Anxiolytics (N05B), Beta-lactam antibacterials, penicillins (J01C) |
| 3 | 875 | 3.1% | 0.1% | 15.1% | 2.6% | 97.4% | Angiotensin II receptor blockers (ARBs), plain (C09C), Blood glucose lowering drugs, excl. insulins (A10B), Lipid modifying agents, plain (C10A), Selective calcium channel blockers with mainly vascular effects (C08C), Insulins and analogues (A10A) |
| 4 | 17,751 | 62.9% | 74.8% | 15.1% | 95.2% | 4.8% | Antithrombotic agents (B01A), Other analgesics and antipyretics (N02B), Beta blocking agents (C07A), Opioids (N02A), Lipid modifying agents, plain (C10A), High-ceiling diuretics (C03C), Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B), Other beta-lactam antibacterials (J01D), Insulins and analogues (A10A), Blood glucose lowering drugs, excl. insulins (A10B), Hypnotics and sedatives (N05C), Drugs for constipation (A06A), Selective calcium channel blockers with mainly vascular effects (C08C) |
| 5 | 937 | 3.3% | 0.0% | 16.6% | 0.0% | 100.0% | Stomatological preparations (A01A), Antithrombotic agents (B01A), Other analgesics and antipyretics (N02B), Topical products for joint and muscular pain (M02A), Angiotensin II receptor blockers (ARBs), plain (C09C), Lipid modifying agents, plain (C10A), Blood glucose lowering drugs, excl. insulins (A10B), Selective calcium channel blockers with mainly vascular effects (C08C), Insulins and analogues (A10A) |
| 6 | 436 | 1.5% | 0.0% | 7.7% | 0.7% | 99.3% | Stomatological preparations (A01A), Lipid modifying agents, plain (C10A), Antithrombotic agents (B01A), Topical products for joint and muscular pain (M02A), Other analgesics and antipyretics (N02B), Blood glucose lowering drugs, excl. insulins (A10B), Selective calcium channel blockers with mainly vascular effects (C08C), Insulins and analogues (A10A), Angiotensin II receptor blockers (ARBs), plain (C09C) |
*All patients used for the clustering of medication data set. **Medications with at least 60% prevalence in the cluster are presented in descending order of prevalence out of 84 medication codes used for VAE model training.
Proportion out of data set describes how the RWD and RCT patients are distributed along the different clusters. Cluster breakdown shows how large proportions of the patients belonging to a cluster come from RWD and RCT sets.